The National Alliance of Advocates
for Buprenorphine Treatment

Buprenorphine (Suboxone®, Subutex®3, Zubsolv™4, Probuphine®5) is an opioid medication used to treat opioid addiction in the privacy of a physician's office.1 Buprenorphine can be dispensed for take-home use, by prescription.1 This, in addition to the pharmacological and safety profile of buprenorphine, makes it an attractive treatment for patients addicted to opioids.2

Entries for month: December 2011

Maine rations addiction treatment via Medicaid

Buprenorphine News 8 Comments »

A cost-cutting task force is considering a two-year limit on Medicaid coverage for buprenorphine treatment for addiction which would force many current, stable patients to taper off this lifesaving medication within 30 days. Maine’s proposal is especially disturbing when you consider these two very important news releases last month. First, the CDC reports prescription drug overdose deaths are on the rise, with opioid painkiller overdoses accounting for 40 deaths a day nationwide. Second, the largest study to date of Suboxone used for the treatment of prescription drug addiction produced positive results. The study clearly shows that when this effective treatment is discontinued, and thus no longer suppressing the symptoms of addiction, symptoms return placing patients at risk of death from overdose. This confirms that chronic treatment may be appropriate for the chronic condition of addiction. These results will not come as a surprise to medical professionals or patients involved with opioid addiction or buprenorphine treatment, but appear to not even be a consideration of Maine’s task force.....


The Purpose of Buprenorphine Treatment:

To suppress the debilitating symptoms of cravings and withdrawal, enabling the patient to engage in therapy, counseling and support, so they can implement positive long-term changes in their lives which develops into the new healthy patterns of behavior necessary to achieve sustained addiction remission. - explain -

The National Alliance of Advocates for Buprenorphine Treatment is a non-profit organization charged with the mission to:

  1. U.S. Food and Drug Administration, FDA Talk Paper, T0238, October 8, 2002, Subutex and Suboxone approved to treat opiate dependence.
  2. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.
  3. Subutex Discontinued in the US market in late 2011.
  4. Zubsolv (bup/nx sublingual tablet) FDA approved 7/3/2013 see buprenorphine pipeline graphic -in pharmacies now.
  5. Bunavail (bup/nx bucal film) FDA approved 6/6/2014 see buprenorphine pipeline graphic -in pharmacies now.
  6. Probuphine FDA approved 5/26/2016 - FDA Probuphine press release